NEWS & INSIGHTS /

Ashley Lakner, CSO: “The partnership with Servier opens new opportunities to identify therapeutic targets for glioblastoma”

Glioblastoma

The science

Publication Date:
TO READ NEXT

How Exceptional Glioblastoma Survivors Could Help Identify New Therapeutic Targets

By analyzing the biology of exceptional glioblastoma survivors, Cure51 and Servier aim to uncover mechanisms of survival that could help develop new treatments for glioblastoma patients worldwide.

Ashley Lakner, Phd, Chief Scientific Officer, Cure51


Updated: September 24, 2026

Table of Contents
in THIS ARTICLE
In this article

Ashley Lakner, PhD

Chief Scientific Officer

MORE ARTICLES IN THIS TOPIC
RELATED ARTICLES

Glioblastoma vs. Glioma: the Full Guide to Understanding Glioma, GBM and the Future of Research

Glioblastoma vs. Glioma: the Full Guide to Understanding Glioma, GBM and the Future of Research

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

https://shining-circumstances-346837.framer.app/news/crispr-cas9-cancer-target-discovery

How CRISPR-Cas9 helps validate cancer targets

https://shining-circumstances-346837.framer.app/news/crispr-cas9-cancer-target-discovery

How CRISPR-Cas9 helps validate cancer targets

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

READ MORE

MORE TOP STORIES
marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

Building a Product Ecosystem for Cancer Target Discovery

CHUV-Centre-hospitalier-universitaire-vaudois

CHUV Lausanne received their Rosalind trophy!

precision-medicine-nicolas-wolikow

Our CEO Nicolas Wolikow: "Turning precision medicine into an operational reality"

NEWS & INSIGHTS

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

We’re thrilled to announce a major milestone for Cure51: a strategic collaboration with Servier to uncover new therapeutic targets in glioblastoma

READ MORE

MORE TOP STORIES

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

Building a Product Ecosystem for Cancer Target Discovery

marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

CHUV Lausanne received their Rosalind trophy!

CHUV-Centre-hospitalier-universitaire-vaudois

Our CEO Nicolas Wolikow: "Turning precision medicine into an operational reality"

precision-medicine-nicolas-wolikow

How Cure51 Builds a Global Cancer Research Project Across 50+ Countries

Global-Cancer-Research-Compliance

NEWS & INSIGHTS

UNTIL ALL SURVIVE.

From frontline caregivers and patients to researchers and media voices, we bring diverse perspectives together to advance cancer research. Let’s talk.

Contact us

UNTIL ALL SURVIVE.

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.

©2024 Cure51, All Rights Reserved

©2026 Cure51, All Rights Reserved

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.

Follow us

Linkedin

Facebook

Instagram

Contact us

Contact us

Follow us

Linkedin

Facebook

Instagram

Contact us

ROSALIND

Contact us